Merck & Co., Inc. (NYSE:MRK) is one of the 12 Best Dogs of the Dow to Invest in, according to Insider Monkey. BofA recently raised its price target on Merck to $120 from $105 and maintained a Buy rating, citing a more appealing pipeline and new valuation based on a FY27 EPS estimate. Despite challenges such as declining sales of HPV vaccines and increased competition for Keytruda, Merck is actively expanding its pipeline with new approvals, like the pneumonia vaccine Capvaxive, which brought in $244 million in sales in the third quarter. The company remains focused on discovering, developing, and delivering medicines, vaccines, and animal health products globally.

Read more at Yahoo Finance.: BofA Turns More Positive on Merck (MRK) Pipeline